FORM 8-K
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): February 27, 2006 (February
21, 2006)
SKYSTAR
BIO-PHARMACEUTICAL
COMPANY
(Exact
name of registrant as specified in Charter)
|
Nevada
|
|
000-28153
|
|
33-0901534
|
|
(State
or other jurisdiction of
incorporation
or organization)
|
|
(Commission
File No.)
|
|
(IRS
Employer Identification
No.)
|
Rm.
10601, Jiezuo Plaza, No.4, Fenghui Road South,
Gaoxin
District, Xian Province, P.R. China
(Address
of Principal Executive Offices)
(407)
645-4433
(Issuer
Telephone Number)
THE
CYBER GROUP NETWORK CORPORATION
(Former
name or former address, if
changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Forward
Looking Statements
This
Form
8-K and other reports filed by Skystar Bio-Pharmaceutical Company (the
“Registrant”) from time to time with the Securities and Exchange Commission
(collectively the “Filings”) contain forward looking statements and information
that are based upon beliefs of, and information currently available to, the
Registrant’s management as well as estimates and assumptions made by the
Registrant’s management. When used in the Filings the words “anticipate”,
“believe”, “estimate”, “expect”, “future”, “intend”, “plan” or the negative of
these terms and similar expressions as they relate to the Registrant or the
Registrant’s management identify forward looking statements. Such statements
reflect the current view of the Registrant with respect to future events and
are
subject to risks, uncertainties, assumptions and other factors relating to
the
Registrant’s industry, operations and results of operations and any businesses
that may be acquired by the Registrant. Should one or more of these risks or
uncertainties materialize, or should the underlying assumptions prove incorrect,
actual results may differ significantly from those anticipated, believed,
estimated, expected, intended or planned.
| Item
4.01 |
Changes
in Registrant's Certifying
Accountant
|
Effective
February 21, 2006, GC Alliance Limited
(“GC
Alliance”) was dismissed as
Skystar Bio-Pharmaceutical Company’s (the “Registrant”) principal accountant
engaged to audit the Registrant’s financial statements. GC Alliance Limited did
not audit or review any of the Registrant’s financial statements. Prior to their
dismissal, there were no disagreements with GC Alliance on any matter of
accounting principles or practices, financial statement disclosure or auditing
scope or procedure, which disagreements if not resolved to the satisfaction
of
GC Alliance would have caused them to make reference to this subject matter
of
the disagreements in connection with their report, nor were there any
"reportable events" as such term as described in Item 304(a)(1)(iv) of
Regulation S-B, promulgated under the Securities Exchange Act of 1934, as
amended ("Regulation S-B").
The
Registrant has requested GC Alliance to furnish it with a letter addressed
to
the SEC stating whether it agrees with the statements made above by the
Registrant. A copy of such letter will be filed as an amendment to this Form
8-K
when received from GC Alliance.
Effective
on February 21, 2006, the Registrant engaged Moore
Stephens Wurth Frazer & Torbet LLP (“Moore Stephens”), whose address is
1199
South Fairway Drive, 2nd Floor, Walnut, California 91789,
was
engaged to serve as
the
Registrant's new independent accountant to audit the Registrant's financial
statements. The decision to retain this accountant was approved by the Company’s
Board of Directors.
Prior
to
engaging Moore Stephens, the Registrant had not consulted Moore Stephens
regarding the application of accounting principles to a specified transaction,
completed or proposed, the type of audit opinion that might be rendered on
the
Registrant’s financial statements or a reportable event, nor did the Registrant
consult with Moore Stephens regarding any disagreements with its prior auditor
on any matter of accounting principles or practices, financial statement
disclosure, or auditing scope or procedure, which disagreements, if not resolved
to the satisfaction of the prior auditor, would have caused it to make a
reference to the subject matter of the disagreements in connection with its
reports.
The
Board
of Directors of Registrant approved the change in accountants described herein
on February 21, 2006.
| Item
9.01 |
Financial
Statements and Exhibits
|
|
Exhibit
Number
|
|
Description
|
|
|
|
|
|
16.1
|
|
Letter
from GC Alliance Limited dated February __, 2006.
*
|
| |
|
|
___________
*
To be
filed by amendment.
[Signatures
Page Follows]
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
Date: February
27, 2006
|
Skystar
Bio-Pharmaceutical Company
(Registrant)
|
| |
|
|
| |
By:
|
/s/
Weibing Lu
|
|
|
Weibing
Lu
|
|
|
Chief
Executive Officer
|